APEXLABS
Back to Research Library
Fat Loss

Tesamorelin and Adipose Tissue: What Researchers Are Finding

8 min readJanuary 25, 2026

What Is Tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids. It includes a trans-3-hexenoic acid modification at the tyrosine residue, which increases its stability and biological activity compared to native GHRH.

Mechanism of Action

Tesamorelin acts through the hypothalamic-pituitary axis:

  • GHRH receptor binding: Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and release of endogenous growth hormone.
  • Pulsatile GH release: Unlike exogenous GH administration, tesamorelin promotes a more physiological, pulsatile pattern of GH secretion.
  • IGF-1 elevation: As a GH secretagogue, tesamorelin indirectly increases IGF-1 levels through enhanced GH production.

Research on Visceral Adipose Tissue

The primary area of tesamorelin research has focused on visceral adipose tissue (VAT):

  • VAT reduction: Studies have demonstrated significant reductions in trunk fat and visceral adipose tissue in treated subjects compared to placebo.
  • Selective fat reduction: Research shows tesamorelin preferentially reduces visceral fat without significant changes in subcutaneous adipose tissue.
  • Metabolic markers: Some studies have observed improvements in triglyceride levels and other metabolic parameters alongside VAT reduction.

Study Design Considerations

Researchers studying tesamorelin should consider:

  • Measurement methods: CT imaging and DEXA scanning are the gold standard for quantifying visceral adipose tissue changes.
  • Duration: Most studies examining body composition changes run for 12-26 weeks to observe meaningful changes.
  • Biomarkers: IGF-1 levels serve as a pharmacodynamic marker confirming biological activity.
  • Washout effects: Studies have shown that VAT reduction effects may reverse after treatment discontinuation, an important consideration for study design.

Conclusion

Tesamorelin represents a well-characterized GHRH analogue with a specific research focus on visceral adipose tissue metabolism. Its mechanism of promoting endogenous GH release in a pulsatile pattern distinguishes it from direct GH administration and makes it a valuable research tool for studying the GH-IGF-1 axis.